I-131 Treatment for Hyperthyroidism
DCEG investigators conduct a study of 35,573 patients treated for hyperthyroidism to determine whether post-therapeutic leukemia or other malignancies occurred more often in patients receiving Iodine-131 treatment compared to patients receiving antithyroid drugs or surgery.
To reconstruct the organ doses due to oral administration of Iodine-131, DCEG dosimetrists developed a new biokinetic model for iodine for hyperthyroid patients. Parameters of the model were obtained from results of measurements of iodine in blood, urine, and the thyroid following treatments for thyrotoxicosis for 3,138 patients. For these patients with available measured data, the individual organ doses were calculated based on the administered activity of Iodine-131 and the predictions of the amounts of iodide and protein-bound-iodine present in each organ and tissue, as well as the biological behavior of iodine in the body. Estimation of organ doses to all cohort members is in progress.
For more information, contact Cari Kitahara.